LYON, France, Oct. 24 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP - News), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced the publication of three new articles further confirming the company's position as the preeminent provider of HIFU therapy for localized prostate cancer. The articles detail the repeatability of top level outcomes at new centers from the start of service, lower side effects including a 69% preservation of potency using Ablatherm-HIFU and the safety of repeating HIFU therapy in patients who may require follow up care.
